CelLBxHealth plc
ANPCYOTCHealthcare
$0.07
+$0.00(+0.00%)
Market Cap$21976000
P/E Ratio—
52W High$2.39
52W Low$0.0666
CelLBxHealth plc (ANPCY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANPCY · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Sep 9, 2025EPS Actual
-$0.39
Revenue
$0.00B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Sep 9, 2025
After Market Close
ANPCY reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q3 FY2025 | Sep 9, 2025 | — | -$0.39 | — | $0.00B | — | — |
| — Q2 FY2025 | May 28, 2025 | — | -$0.01 | — | $0.00B | — | — |
| ◌ Q4 FY2024 | Oct 24, 2024 | — | — | — | — | — | — |
| — Q3 FY2024 | Sep 26, 2024 | — | -$0.02 | — | $0.00B | — | — |
| — Q2 FY2024 | Jun 5, 2024 | — | -$0.02 | — | $0.00B | — | — |
| — Q1 FY2024 | Mar 19, 2024 | — | -$0.05 | — | $0.00B | — | — |
| — Q1 FY2024 | Feb 7, 2024 | — | -$0.02 | — | $0.00B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.05 | — | $0.00B | — | — |
Q3 FY2025
Sep 9, 2025
EPS Actual
-$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 28, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Oct 24, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 26, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Jun 5, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2024
Mar 19, 2024
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2024
Feb 7, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Sep 9, 2025 | — | $0.82 | $0.63 | -23.52% |
| — Q2 FY2025 | May 28, 2025 | — | $1.10 | $1.10 | +0.00% |
| — Q3 FY2024 | Sep 26, 2024 | — | $1.12 | $1.25 | +11.61% |
| — Q2 FY2024 | Jun 5, 2024 | — | $2.39 | $2.39 | +0.00% |
| — Q1 FY2024 | Mar 19, 2024 | — | $1.80 | $1.89 | +5.00% |
| — Q1 FY2024 | Feb 7, 2024 | — | $1.86 | $1.86 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $1.51 | $1.51 | +0.00% |
| — Q2 FY2023 | Apr 21, 2023 | — | $2.40 | $3.40 | +41.67% |
Q3 FY2025-23.52%
Report Date
Sep 9, 2025
EPS Beat/Miss
—
Price Before
$0.82
Price After
$0.63
Q2 FY2025+0.00%
Report Date
May 28, 2025
EPS Beat/Miss
—
Price Before
$1.10
Price After
$1.10
Q3 FY2024+11.61%
Report Date
Sep 26, 2024
EPS Beat/Miss
—
Price Before
$1.12
Price After
$1.25
Q2 FY2024+0.00%
Report Date
Jun 5, 2024
EPS Beat/Miss
—
Price Before
$2.39
Price After
$2.39
Q1 FY2024+5.00%
Report Date
Mar 19, 2024
EPS Beat/Miss
—
Price Before
$1.80
Price After
$1.89
Q1 FY2024+0.00%
Report Date
Feb 7, 2024
EPS Beat/Miss
—
Price Before
$1.86
Price After
$1.86
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$1.51
Price After
$1.51
Q2 FY2023+41.67%
Report Date
Apr 21, 2023
EPS Beat/Miss
—
Price Before
$2.40
Price After
$3.40
Beat Rate0 / 8 quarters
Largest Move+41.67% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANPCY ends December
CelLBxHealth plc (ANPCY) most recently reported earnings on September 9, 2025 for Q3 FY2025, posting EPS of $-0.39 (in line with the analyst consensus of —). The next ANPCY earnings date is expected around September 1, 2026.
Each quarter, investors track ANPCY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANPCY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANPCY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANPCY earnings · 4 questionsCelLBxHealth plc's next earnings report is expected around September 1, 2026. ANPCY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANPCY historically reports after market close (AMC).
ANPCY earnings datewhen is ANPCY earningsANPCY next earnings datewhen does ANPCY report earningsANPCY earnings calendar
▸ Source: FMP · CelLBxHealth plc SEC filings · US GAAP · CelLBxHealth plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026